Companies

Semiconductors

Advanced Micro Devices

The number-two AI compute franchise is finally real (DC $16.6B FY25, MI450/OpenAI 6GW signed) — but at ~58x forward EPS with 320M warrant shares of dilution overhang and an analyst PT below spot, the stock has already priced the win. WATCHING, not chasing.

Robotics

Aeva Technologies

A genuine FMCW technology lead and a watershed exclusive-OEM win, priced at ~28x forward sales against ~24 months of runway and a 2028 start-of-production — the technology is real, the chasm between here and revenue is the trade.

Agtech

AGCO

A cycle-trough, Europe-funded margin story trading at a deserved peer discount — own it for the 2026-27 ag recovery and the PTx self-help, but the entire thesis rests on EME holding up while North America bleeds tariff dollars and PTx Trimble proves it isn't a $2B impairment-in-waiting.

Critical Materials

Alcoa

A genuinely deleveraged, vertically-integrated aluminum pure-play whose 2025-26 earnings recovery is being borrowed from a tariff — ~60% of US aluminum volume rides a Section-232-inflated Midwest premium that is a policy decision away from evaporating; own the cycle, not the multiple.

Genomics

Alnylam Pharmaceuticals

The first RNAi company to scale to profitability — Amvuttra's ATTR-CM launch turned a 20-year science project into a >$5B-revenue franchise inflecting at +71% guided; the bet is whether durable TTR leadership + a 40-program pipeline justify ~70x forward earnings before nucresiran fixes the Sanofi royalty drag.

AI & Machine Learning

Alphabet

The market spent two years pricing Alphabet as the AI loser; FY2025 (+15% op income, Cloud margin to 24%, Gemini at 750M users, the antitrust gun mostly de-cocked) proves it owns the full stack — but at $4.5T and a fresh $90B+ capex habit, the easy re-rating is now behind it and the bar is "monetize the buildout.

Biopharma

Altimmune

A single-asset MASH/AUD/ALD bet on a glucagon/GLP-1 dual agonist that wins on liver biology and lean-mass-sparing but loses on raw weight loss — fully funded into 2028 with a binary AUD readout in Q3 2026 as the next free option; a derisked, heavily-shorted optionality vehicle, not a fundamentals compounder.

AI & Machine Learning

Amazon (AWS)

The neutral arms-dealer of the AI build-out — AWS + Trainium + a stake in both OpenAI and Anthropic is the best-positioned compute franchise on Earth, but free cash flow has been incinerated to ~$1B and a ~$200B 2026 capex bet on 5-year-depreciated silicon is the whole thesis.

Semiconductors

Ambarella

A genuine edge-AI vision SoC franchise finally inflecting to growth and operating leverage — but it is still GAAP-unprofitable, ~70% revenue routes through one distributor, and the stock prices both a re-acceleration AND an unresolved M&A bid. Quality asset, demanding price, binary catalyst.

Crypto & Digital Assets

American Bitcoin

A Trump-branded, Hut-8-controlled bitcoin-accumulation SPV that sells equity to buy BTC and rents its mining from its parent — a ~3x-mNAV levered BTC proxy with no AI optionality, now down ~94% and asking holders for a 1-for-40 reverse split.

Biopharma

Amgen

A levered dividend-compounder running a patent-cliff relay race — the legacy book (>40% of revenue under biosimilar/IRA attack) is being out-sprinted by Repatha/rare-disease/oncology launches, but the equity is priced for MariTide to win the obesity prize it most likely places, not wins, in.

Semiconductors

Amphenol

A 90-year connector compounder that the market has re-rated into an AI-infrastructure growth stock — the business is exceptional and the AI cycle is real, but at ~34x forward EPS and 50% above its own decade-average multiple, the price already pays Amphenol to keep printing 30%+ organic growth, leaving no cushion if hyperscaler capex normalizes.

Energy

Amprius Technologies

A real, first-mover aviation/drone battery franchise inflecting to its first profitable year — but priced at ~17x guided 2026 sales with a China related-party supplier (Berzelius, ~36% of COGS, tied to the founder) now the subject of an active short report; the franchise is bullish, the stock is a show-me on revenue quality.

Semiconductors

Applied Materials

The cheapest of the four equipment leaders riding a re-accelerating AI/GAA WFE upcycle — but the entry is a 4x-off-the-low all-time high, and the bet is whether the >30% 2026 equipment-growth guide is the new floor or a cycle peak being paid for in advance.

Cloud Computing

Applied Optoelectronics

A real but sub-scale optical-transceiver share-gainer whose AI-data-center inflection is genuine — but the equity is priced as if it has already won a market that InnoLight, Coherent and Lumentum actually own, while it funds the build with relentless dilution and parks three-quarters of its receivables on one distributor (Digicomm) on stretched terms. The 2017 Amazon-loss crash is the template, not the exception.

Energy

Array Technologies

A profitable-at-the-EBITDA-line, 100%-domestic-content solar-tracker #2 trading at half Nextracker's multiple — but the equity is a thin slice trapped beneath $400M of compounding 6.25%→cash preferred, a collapsed Brazil segment, and a 2026 OBBB safe-harbor cliff that turns its record order book into a coin-flip on timing.

Genomics

Arrowhead Pharmaceuticals

A platform-validated RNAi engine the Street prices as a partnering machine, not a commercial one — the entire bull case is whether plozasiran's sHTG sNDA (YE2026) turns a $15.2B milestone option-stack into owned product P&L before the 15% PIK debt and serial dilution grind down the equity.

Semiconductors

ASML Holding

The one company AI cannot route around — a literal EUV monopoly compounding at mid-teens with a fortress balance sheet, priced at ~55x for perfection while the only real bear (a China DUV ban naming ASML in statute) caps the downside at ~5% of revenue. Own the moat; respect the multiple.

Energy

ASP Isotopes

A pre-revenue isotope-enrichment story trading on three real Western-monopoly catalysts (Yb-176, Si-28, HALEU) — but the FY25 "revenue" was construction it has since deconsolidated, the GAAP loss is a $124M convertible-note mark, and the tape is a 22%-short battleground stuck in active securities-fraud litigation. The science could be a generational supply-chain unlock; the accounting and promotion are exactly what shorts say they are. WATCHING, not yet ownable.

Cloud Computing

Astera Labs

A genuine pick-and-shovel monopoly on PCIe-Gen6 datacenter connectivity, growing 90%+ with 76% gross margins — but priced at ~26x forward sales with one customer (AWS) at ~70% of revenue; the moat is real, the price is the bet.

Optical Computing

AXT Inc

A real, scarce, China-gated InP asset that AI-optics demand made strategic — but the stock already priced an ~80x melt-up to a ~$5.9B cap on an $88M-revenue, loss-making, single-country-manufacturing base; the asset is genuine, the multiple is a dare.

AI-Bio

Bicycle Therapeutics

A debt-free clinical biotech trading below net cash after the FDA rejected its lead's trial design — the platform and a 4-year runway are free, but only if the EphA2/radioconjugate pivot proves the machine can make a second winner.

Biopharma

BioAge Labs

A burned-then-reborn aging-biology platform whose entire ~$730M cap now rests on one Phase 1 asset (oral brain-penetrant NLRP3 inhibitor BGE-102) printing best-in-class hsCRP — fully funded to 2029, but the value-creating Phase 2 readouts are still 6-18 months out and a Lilly-backed competitor (ex-Ventyx) is the same molecule class with deeper pockets.

Agtech

Bioceres Crop Solutions

A real ag-biologicals franchise (Rizobacter) trapped inside an over-levered Cayman holdco in going-concern doubt — creditors are credit-bidding the US crown jewels for cents, $222M of debt matures in FY2026 against $14M cash, and the equity at $0.42 is a near-worthless option on a restructuring, not an investment in the science.

Genomics

BioNTech

A €17bn cash fortress wrapped around a melting COVID annuity and one make-or-break fast-follower oncology bet (pumitamig) — the founders just announced they're walking out the door, and the market still pays a premium for a pipeline that is, so far, the second-best PD-(L)1×VEGF in the world.

Crypto & Digital Assets

BitMine Immersion Technologies

A leveraged Ethereum proxy that lives and dies on the mNAV premium — and the premium is already gone (trading ~0.75–0.89x NAV), turning the equity-issuance flywheel into a dilution headwind on a $9–10B ETH bet audited by a two-person Nevada CPA shop.

Neurotech & BCI

Butterfly Network

A genuine semiconductor moat wrapped around a sub-scale, still-unprofitable medtech — the Midjourney/Embedded licensing pivot is real and re-rates the story, but at ~10x forward sales with episodic licensing revenue and a founder selling, the price already imputes the platform it has not yet proven.

Crypto & Digital Assets

Canaan

A real #3 ASIC maker that just clawed back to gross profit and product parity with Bitmain — but it is a sub-$1 going-concern call masquerading as a turnaround, where serial equity dilution and a hashprice depression decide the outcome long before the A16 does.

Robotics

Celestica

Not a robotics name — the purest large-cap pick-and-shovel on AI back-end networking (800G→1.6T switches + custom hyperscaler racks), compounding adjusted EPS ~45%/yr; but ~65% of revenue sits in three hyperscalers and the stock already prices ~37x forward, so the bet is "does hyperscaler capex and Celestica's share survive a single-customer wobble" rather than "is there demand.

Critical Materials

Centrus Energy

The only U.S.-owned enrichment platform with an NRC HALEU license and a $900M DOE expansion award — but it is still a sub-scale fuel broker living on a Russian supply contract that dies in 2028, priced at 50–60x earnings for a build-out that is contingent on money it does not yet have.

Critical Materials

Century Aluminum

The single most tariff- and operationally-levered way to own a structurally walled-off US aluminum price — a high-beta, low-EV/EBITDA call levered to a record Midwest premium, gated by a Glencore-controlled cap table, a Jamalco material weakness, and a hedge book bleeding against its own thesis.

AI-Bio

Certara

A real, regulator-embedded biosimulation moat trading like a broken SaaS roll-up — but the bet only works if the new CEO can re-accelerate software past the +7% Q1 stall before the M&A floor (SLP at 2.5x) is the only thing holding the stock.

Crypto & Digital Assets

Cipher Mining

A bitcoin miner that has successfully optioned itself into an AI landlord — $11.4B of hyperscaler lease backlog backstopped by Google and Amazon is real, but the equity is priced for flawless execution of a buildout that hasn't started cashing rent, and the whole thesis is a bet on shovels-in-the-ground beating the sector's 25%-delivered track record.

Crypto & Digital Assets

Circle Internet Group

A high-quality, regulation-first stablecoin franchise priced as a fintech but earning like a leveraged bond fund — the entire thesis now hangs on two August 2026 events (the Coinbase renegotiation and the rate path), and at ~$80 the market is paying for a re-rating that requires Circle to win both.

Crypto & Digital Assets

CleanSpark

A best-in-class US bitcoin miner that has rebuilt itself into a 0%-convert-funded, share-shrinking BTC-beta vehicle now sprinting late into the AI/HPC pivot — the equity is a leveraged call on bitcoin and on executing a datacenter business that today earns exactly $0.

Critical Materials

Cleveland-Cliffs

A leveraged, blast-furnace cyclical printing its worst losses since the acquisition spree — but the tariff-supported price floor is already bending the loss curve up, and the stock has nearly doubled off the low pricing much of that recovery in. Bullish on the operating turn, but the debt + dilution + cash-burn make this a high-beta option, not a compounder.

Agtech

CNH Industrial

A structurally-sound #2 ag-equipment franchise at trough earnings and a 0.84x EV/Sales — but the bull case rests on a 2027 cyclical recovery that tariffs, a self-inflicted precision-tech gap vs Deere, and Brazil credit stress can each defer. WATCHING — own the cycle turn, not the current print.

AI-Bio

Codexis

A real platform with a lottery ticket attached — the legacy biocatalysis P&L is shrinking and the entire equity is a bet that enzymatic siRNA manufacturing (ECO Synthesis) becomes the standard before the cash runs out in 2027; the 4x off the $0.96 March low has front-run any GMP revenue.

Cloud Computing

CoreWeave

The largest independent AI neocloud — renting NVIDIA compute to OpenAI, Microsoft and Meta under $60B of contracts, financed by an equally vast pile of debt.

Optical Computing

Credo Technology

A real moat in AEC reliability and an n-1 cost edge, riding a verticalizing AI-interconnect ramp — but ~84% of revenue sits in three hyperscalers and ~41x forward earnings already prices in the optical pivot working. Bullish business, expensive stock; conviction gated on customer diversification proving out.

Genomics

CRISPR Therapeutics

The only commercial CRISPR company is a Vertex-controlled 40% royalty stub bolted to a self-funded in-vivo pipeline — own it for CTX310/zugo-cel optionality, not for Casgevy, whose cell-collection bottleneck caps the near-term cash story.

Crypto & Digital Assets

DeFi Development Corp

A levered Solana proxy whose only value-creation engine — issuing stock above NAV to buy SOL — has stalled exactly as mNAV collapsed to ~1.0x; below par the flywheel runs in reverse and the $83M Q1 equity wipeout, three material weaknesses, and a SOL-collateralized margin book make this a forced-deleveraging short into the next SOL drawdown.

Biopharma

Denali Therapeutics

First-ever blood-brain-barrier biologic just got approved (AVLAYAH, Mar 2026) — Denali is now a de-risked platform with a small rare-disease revenue base, but the May LUMA Parkinson's failure gutted the biggest pipeline call option, so you're paying $3.3B for a ~$525M-peak orphan drug plus optionality the market just learned to distrust.

Genomics

Editas Medicine

A foundational-CRISPR IP estate wrapped around a single, late-arriving preclinical asset (EDIT-401) — a binary 2026-2027 LDLR bet that is years behind Lilly/Verve, now fully funded into 2027+ by a May 2026 raise that diluted holders ~25%; the moat is real, the pipeline is not yet.

Energy

Enovix

A pre-commercial silicon-anode battery story trading at ~$1.6B on $32M of lumpy Korean-defense revenue — the entire thesis is one flagship smartphone qualification that keeps slipping; brilliant architecture and an A-list mobile CEO, but until a real OEM ships, this is a binary, dilution-exposed option, not a business.

Energy

Eos Energy Enterprises

A real zinc-battery business is finally being born inside a financial engine that mints non-cash "profits" while burning ~$120M/quarter in cash and diluting holders 49% a year — own the inflection only if you believe COGS crosses below revenue before the Cerberus-and-convert capital structure swallows the equity.

Biopharma

Equillium, Inc.

A two-asset preclinical option on EQ504 (gut-restricted AhR modulator for UC) wrapped in a >3yr cash runway and tier-1 (RA Capital / Decheng) sponsorship — but at ~$130–185M EV the market is paying real money for a drug no human has yet taken; the entire thesis lives or dies on the mid-2026 Phase 1 PoM readout ~early 2027.

Crypto & Digital Assets

Figure Technology Solutions

The best-run business in tokenized credit — a real, ~50%-EBITDA-margin lending-tech engine wearing a crypto multiple — but it is one HELOC product, one founder's super-vote, fresh material weaknesses and a million-record breach away from re-rating the wrong way; great company, priced like a story, own it cheaper.

Energy

First Solar

The best-run solar manufacturer on earth, but ~$1.6B of FY25's $1.5B net income is a US tax credit — you are not buying a module company, you are buying a leveraged, policy-dated bet that the 45X subsidy and the domestic-content wall hold through 2032.

Electrification

Fluence Energy

A levered call option on US grid-storage demand and IRA/OBBBA domestic-content rules — record $5.6B backlog and two hyperscaler deals validate the funnel, but 7–13% gross margins, a 50%-H2-weighted year, and a stock above the average analyst target leave it priced for flawless execution it has repeatedly failed to deliver.

Critical Materials

Freeport-McMoRan

A world-class copper-and-gold orebody wrapped in a structurally leaky holding company — you buy FCX for the copper supercycle and the Grasberg restart, but ~half of every Indonesian dollar exits to the Indonesian state before it reaches your share, and Grasberg execution (not the copper price) is what actually decides the stock through 2027.

Energy

FuelCell Energy

A 28-year-unprofitable, perpetually-dilutive fuel-cell manufacturer re-rated 135% YTD on an AI-data-center pipeline that is still non-binding LOIs — the story is real, the order book is not, and the funding model is the share count.

Crypto & Digital Assets

Galaxy Digital

Two companies stapled together — a volatile crypto merchant bank wrapped around an emerging West-Texas AI-datacenter annuity (CoreWeave, >$1B/yr × 15yr); the stock has decoupled from bitcoin and now trades the Helios optionality, but CoreWeave single-tenant concentration plus a marked-to-market house book make conviction event-dependent, not durable.

Crypto & Digital Assets

Gemini Space Station

A sub-1%-share, structurally subscale crypto exchange whose core trading revenue is already flat — kept alive by recurring related-party rescue financing from its own founders; the ~85% post-IPO drawdown is the market correctly re-rating a $3.3B IPO to a ~$0.5B going concern, and nothing in the numbers says the floor is in.

Space

Gilat Satellite Networks

A balance-sheet roll-up of the fragmenting Western defense-satcoms supply chain (DataPath→Stellar Blu→Comtech) wrapped around an orbit-agnostic ground-terminal franchise that wins whether GEO or LEO wins — but the stock already prices the re-rating (~23x EV/EBITDA) while organic margins are still convalescing and two customers are 44% of revenue.

AI & Machine Learning

Google DeepMind (Alphabet)

Critical Materials

GrafTech International

A levered, structurally-loss-making graphite-electrode pure-play whose old take-or-pay earnings are gone, now priced as a distressed call option on a 2026 electrode-price recovery that has to clear a 2029 debt wall — own the bonds' problem, not the equity, until pricing turns or the balance sheet is fixed.

Robotics

Hesai Group

The clear global LiDAR volume leader, now GAAP-profitable and pivoting into physical-AI sensing — but the entire equity is hostage to a single binary it cannot control: the U.S. appeals-court ruling on its DoD "Chinese Military Company" designation, with a hard June 30 2026 contract-ban trigger.

Crypto & Digital Assets

HIVE Digital Technologies

A 25 EH/s green Bitcoin miner that liquidated its entire treasury to fund a credible-but-unfunded pivot to AI compute — the stock now trades on a CAD $3.5B Gigafactory dream that $23M of cash cannot pay for.

Crypto & Digital Assets

Hut 8

A bitcoin miner that quietly turned into a hyperscaler landlord — ~$16.8B of base AA-/Google-credit lease backlog now dwarfs the BTC story, but the equity still trades and bleeds on bitcoin, and the Trump-adjacent ABTC sub is the governance hair.

Neurotech & BCI

Hyperfine

A real, FDA-cleared portable-MRI razor finally finding its blade — Q1 device units +67% and runway into 2028 de-risk the going-concern story, but at ~$22M revenue and a ~$140M cap it is still a sub-scale, founder-controlled call option on point-of-care neuro-imaging, not yet a business.

Genomics

Illumina

A real operational turnaround is underway (rev re-accelerating, margins expanding, share count shrinking), but the stock has already sprinted past consensus into a Roche-Axelios competitive collision and a 40%-NIH-cut research recession — the easy money in the recovery is made.

Robotics

Innoviz Technologies

A real Tier-1 LiDAR product with marquee OEM design wins, trading like an option that expires — the bet is whether VW/Mobileye SOP volume arrives before the Sept-2026 Nasdaq clock and the cash runway force a dilutive reverse split.

Semiconductors

Intel

A barely-profitable IDM whose equity 10x'd on a recapitalization-and-validation narrative (US gov, Nvidia, SoftBank, hyperscaler 18A interest) while Foundry still bled $10.3B in FY25 — the story is priced as if the turnaround already happened. WATCHING, with a bearish lean on valuation.

Genomics

Intellia Therapeutics

A de-risked HAE asset (lonvo-z, 87% attack cut, BLA filing) wrapped in a financing-and-competition problem — the cure is real, the question is whether anyone buys a one-shot in a market with 11 approved drugs, and whether a $1.9B-cap, 38%-shorted clinical-stage burner reaches launch without another dilutive raise.

Crypto & Digital Assets

IREN

A Bitcoin miner that won the AI-infrastructure lottery — NVIDIA both rents IREN's GPUs and bought its equity at $70, validating the liquid-cooling pivot Culper shorted; the bet is now execution and dilution, not survival.

Space

Iridium Communications

A debt-levered, cash-machine LEO monopoly being re-rated on spectrum scarcity — own the durable EMSS/IoT/Aireon annuity, but the spectrum-takeout dream is now mostly in the price.

Critical Materials

Ivanhoe Electric

A single-asset US copper developer (Santa Cruz) levered to a structural copper deficit and the "domestic critical-minerals" trade, wrapped in a Friedland promote and a still-unfunded $1.24B build — own the deposit and the EXIM optionality, but underwrite the dilution, not the PFS NPV.

Robotics

JBT Marel

A newly-merged global #1 in food-processing automation, ~17% off its March high, mid-cycle on a real integration story — the bull case is synergy-and-deleveraging math the market half-believes; the bear case is two unremediated Marel control weaknesses and a $5.4B goodwill/intangible stack sitting on a still-cyclical protein-capex book.

Robotics

Joby Aviation

A funded, certification-stage option on being the first FAA-certified eVTOL — real moat in vertical integration + a fortress balance sheet, but priced for flawless execution with zero core revenue and a binary 2026 catalyst.

Critical Materials

Kaiser Aluminum

The record 2026 print is mostly a Section-232 tariff-premium + metal-price-lag windfall on flat real volume — a high-quality fabricator priced for perfection at a 52-week high after a 2.5x run, with consensus already pointing down.

Space

Karman Holdings

A spec-locked, sole-source space-and-defense subsystem roll-up riding Golden Dome and OBBBA tailwinds at ~50% growth — but it is a leveraged (2.1x D/E) PE-sponsor exit story with a live material weakness, ~$680M of floating-rate debt, and a still-rich ~34x forward EV/Adj-EBITDA; the 58% drawdown is a Trive-Capital supply unwind, not a thesis break. WATCHING (coverage note: this is fundamentally a defense prime-supplier — see exclusion flag).

Semiconductors

Lam Research

Best-in-class etch monopoly riding a once-a-decade memory/AI WFE upcycle into record margins — but at ~69x guided FY26 GAAP EPS the tape, not the business, is the risk; the moat is real, the multiple is borrowed from the future.

AI-Bio

LanzaTech

A real carbon-recycling technology trapped inside a going-concern microcap — the science works, the business model to monetize it does not yet, and the equity is a binary on insiders (Khosla/Brookfield) funding a cohort-licensing pivot to cash-flow breakeven before dilution and Nasdaq erode it to zero. WATCHING with a bearish tilt.

Optical Computing

Lightwave Logic

A 35-year science project that just turned the corner from lab to foundry PDK — credible polymer-photonics platform now inside Tower & GlobalFoundries flows, but $237K of revenue against a $1.5B cap means you are buying a 2027-28 design-win option, financed by perpetual dilution, with a 17.7% short base betting it stays a promise.

Optical Computing

Lumentum

The arms-dealer of the AI optics build-out — Lumentum owns ~50-60% of the 200G/lane EML laser chip that every 1.6T transceiver needs, NVIDIA just bought $2B of preferred to lock its capacity, and revenue is compounding ~90% YoY off a real telecom trough; but at ~52x forward earnings with two customers = ~40% of revenue and a $3.8B convertible stack now in-the-money, the price already discounts flawless execution.

Critical Materials

Materion

An irreplaceable U.S. beryllium monopoly wrapped in a low-margin pass-through metals business and now priced like a secular-growth compounder (~34x fwd vs 18-20x historical, above every Street target) — the asset is real, the multiple is the bet.

Semiconductors

MaxLinear

A real AI-optical DSP ramp (Keystone/Rushmore) bolted onto a flat legacy-broadband body and an unreserved $160M+ arbitration — the stock at $89 already prices the pure-play outcome the income statement hasn't earned; the 80% post-Q1 spike has run past sell-side fair value ($68).

Genomics

MeiraGTx

A de-risked gene-therapy platform hiding inside a $0.85B shell — bota-vec reacquisition + Lilly/Hologen non-dilutive funding gives MeiraGTx three near-term shots (xerostomia BTD, XLRP filing, riboswitch-GLP1 optionality) the market is pricing as one coin-flip; the bet is on execution-to-launch, not science.

AI & Machine Learning

Meta AI / FAIR

The best-funded, worst-priced AI franchise in megacap — a $200B+ ad engine bankrolling a $135B/yr superintelligence bet the market is refusing to underwrite; the stock pays you to wait while the ad-AI flywheel already prints, but the open-weight thesis is dead and the capex ROI clock is now running loud.

AI & Machine Learning

Meta Platforms

The cheapest mega-cap in the AI complex (~18–20x fwd P/E) compounding ad revenue +33% — but it has converted itself into a single-variable bet on whether $125–145B/yr of AI capex earns its return, and the market won't re-rate until the depreciation wave proves out.

Software

Microsoft

Microsoft embedded Anthropic's Claude into M365 Copilot as 'Copilot Cowork' — $30/seat/month for autonomous AI agents that run across your emails, files, and meetings. The $99/seat E7 bundle is Microsoft's play to own the enterprise AI operating system.

Genomics

Moderna

A real mRNA platform priced like an oncology winner before the oncology has won — the +94% YTD melt-up has run past a still-burning, policy-exposed vaccine business with a $1.3B IP tail.

Critical Materials

MP Materials

A subsidized option on Western rare-earth independence — the DoD's $110/kg NdPr floor turned a money-losing concentrate miner into a vertically-integrated magnet company with capped downside, but the equity already prices the 2028+ 10X build at ~134x forward earnings, so you're paying full freight for a thesis that depends on execution and elevated NdPr prices.

Robotics

Myomo

A category-of-one reimbursed medical-robotics razor (myoelectric arm orthosis, 6.3M-stroke US TAM) finally pivoting from cash-burning ad-funded patient acquisition to lower-cost recurring referrals — but it must prove the operating-leverage turn at ~$45M revenue before the Avenue debt covenants and a sub-$1.50 stock force another dilutive raise; bullish on the model, watching the proof.

Genomics

Natera

A category-defining MRD franchise compounding ~35-40% with newly-positive FCF, but priced at ~13x sales for a still-GAAP-unprofitable company whose reported losses are masked only by $350M+/yr of stock dilution and a litigation rap-sheet (a $292.5M Guardant verdict on appeal) that the multiple ignores.

Robotics

Nauticus Robotics

A real subsea-autonomy technology wrapped in a broken micro-cap balance sheet — going concern, a near-empty backlog, Q1-2026 revenue collapsed to $160k, and a board-authorized path to a cumulative 1-for-250 reverse split and 1.5B authorized shares. The tech may survive; today's common stock is a melting ice cube.

Cloud Computing

Nebius Group

A real tier-one neocloud with $46B of Microsoft+Meta backlog and Nvidia equity — but the equity is priced for flawless execution on a $20-25B/yr capex bet funded by debt and customer prepayments, while the auditor just signed an ADVERSE opinion on internal controls.

Energy

Nextpower (ex-Nextracker)

The dominant solar-tracker franchise (>50% US, ~30% global, 11 straight years #1) with a clean, net-cash balance sheet and a beat-and-raise FY26 — but the FY27 guide already flags margin compression, and the whole bull case rests on developers safe-harboring around the OBBBA placed-in-service cliff (Dec 31 2027) plus a 45X manufacturing subsidy (~$380M, ~10% of revenue) that phases out 2030–2032. Quality is not in question; the multiple (~26x forward P/E, ~3x peer ARRY) and the policy clock are.

Energy

NiSource

A boring Indiana gas/electric utility that quietly became an AI-power landlord — ~$28B 2026-30 capex, ~9GW of hyperscaler demand funnelled through a Blackstone-capitalised, ring-fenced GenCo, and a 9-10% EPS CAGR that the market is paying a deserved ~22x for. Own the re-rate; the kill-switch is a hyperscaler walking on the ADS termination option.

Semiconductors

Nova Ltd

A #2 process-control specialist compounding revenue at ~1.7x the market on a structural metrology-intensity tailwind and an AI-memory cycle — but priced at ~35-48x forward earnings with one customer at 23% and a third of sales in export-control-exposed China; own the business, respect the price.

Critical Materials

Nucor

The tariff-fortified, lowest-cost EAF compounder is mid-upcycle with self-help volume still to land — but the +118% run already prices the recovery, so the edge is the multi-year normalized-earnings step-up, not the next print.

Energy

nVent Electric

A boring enclosures-and-connectors company that bought and sold its way into the AI data-center build — now growing 50%+ with infrastructure orders up 100% organically; the re-rating to ~28x is largely earned, but the multiple now prices in the build continuing, and the legacy two-thirds of the business is still cyclical late-cycle industrials.

Semiconductors

NVIDIA

They invented the GPU for gaming. Then they accidentally built the engine that would power the AI revolution—and became the most important semiconductor company in the world.

Cloud Computing

Oracle

While everyone watched OpenAI, Oracle quietly became the cloud backbone that enterprises actually run their AI on. $553B backlog and growing.

Robotics

Ouster

A real, accelerating Western digital-lidar franchise (+49% rev, 43% GM, 13 straight up quarters, June-30 NDAA China ban as a structural tailwind) priced like a winner-take-all at ~15x sales while it still burns cash and lives on serial dilution — own the operating turn, not this multiple.

Genomics

Pacific Biosciences

A long-read pure-play with improving razor-and-blade economics and a real cost roadmap, structurally outrun by Oxford Nanopore and pinned under $641M of out-of-the-money 2029/2030 converts it cannot grow into — a cash-discipline turnaround, not yet an investable one.

AI & Machine Learning

Palantir

A genuinely great business priced as a perfect one — 85% growth and 60% adjusted margins are real, but ~55x EV/Sales already discounts flawless execution for years, so the asymmetry is to the downside even if the thesis is right.

Space

Planet Labs

A commercial-imagery company that quietly became a sovereign-defense satellite-services contractor — the backlog (+72%) and the Rule-of-40 inflection are real, but a $1.5B ATM on top of ~30x sales means the bet is now whether durable government demand outruns relentless dilution.

Genomics

Prime Medicine

A David Liu-pedigreed prime-editing pioneer cornered into a defensive crouch — 25% RIF, founder-CEO out, lead CGD asset demoted to a partnering candidate, going-concern doubt at ~14 months of cash, and an existential Beam IP arbitration over one of its two surviving lead programs. At a ~$537M cap it is a deeply discounted binary call option on 2027 first-in-human liver data; bullish only for risk-seeking capital that can survive a dilution-or-bust 2026.

Robotics

PROCEPT BioRobotics

A single-asset surgical-robotics razor-and-blade compounding ~30% real procedure growth, deliberately torching its own reported revenue to purge channel-stuffed handpieces and install pricing discipline — the half-off de-rate prices in a demand-saturation fear the procedure data does not yet confirm, and a TAVR-category-builder CEO is the call option the tape is ignoring.

Optical Computing

Quantum Computing Inc

A $2.5B market cap on $682K of FY25 revenue — QUBT is a $1.5B treasury wrapped in a photonics R&D lab, sold as a quantum-computing story; the balance sheet is real, the revenue is not, and a securities-fraud class action over the exact gap between the two is unresolved.

Electrification

QuantumScape

A genuine ceramic-separator moat wrapped around a capital-light VW/PowerCo license — but the equity is a $4.4B option on a $130M royalty cheque that has NOT yet been triggered, burning ~$60M/quarter of cash against a binary milestone it does not control.

Neurotech & BCI

Quantum-Si

A first-mover NGPS tools story whose commercial engine is going backwards (revenue −20% in FY25, −69% in Q1'26 to $258K) while it bets the company on Proteus by end-2026; ~$190M cash funds the bet, but a 69%-Rothberg-controlled sub-$1 microcap with collapsing instrument demand is a binary option, not an investment — WATCHING until Proteus ships and consumable pull-through proves real.

AI-Bio

Recursion Pharmaceuticals

The most-instrumented AI drug-discovery platform with the thinnest clinical proof per dollar burned — one real Phase-2 win (REC-4881/FAP) against a $2.2B accumulated deficit, smart-money exiting (NVIDIA, Mubadala out), and a $1.67B market cap that is now a binary bet on Najat Khan converting platform optionality into a registrational asset before the cash runway forces another raise.

AI-Bio

Relay Therapeutics

A genuinely differentiated allosteric PI3Kα asset with a clean ~$642M balance sheet and runway to 2029 — but the entire equity is one Phase 3 readout (ReDiscover-2) into a class that just got a $3B Novartis validation and a first-line Roche incumbent; own the science, respect that the market is pricing a win.

Crypto & Digital Assets

Riot Platforms

A bitcoin miner whose P&L now swings on the BTC mark, not operations — repricing itself as a 1.7 GW AI/HPC power landlord on the back of one $311M AMD lease and a Starboard-pushed pivot; the ~$10.6B cap is paying for an optionality that is still 95% promise.

Crypto & Digital Assets

Robinhood Markets

A real, cash-generative super-app now valued like a crypto-beta call option — the bull thesis (tokenization + a 27M-customer flywheel) is genuine, but ~37x forward earnings re-prices violently every time the crypto/options trading cycle exhales, and the prediction-markets engine that drove Q1 growth is one adverse court ruling from being switched off.

Critical Materials

Royal Gold

A de-risked, debt-light gold royalty toll-bridge that just doubled in size via Sandstorm yet trades at a ~7-9x P/E discount to Franco-Nevada and Wheaton — the discount is the thesis, not the warning.

Space

Satellogic

A $20M-revenue EO manufacturer trading like a $1B growth story on a 200% YTD re-rate — the cost-per-satellite edge and Tether-backed balance sheet are real, but the price already discounts a Merlin success that hasn't launched, and three customers are half the revenue.

Cloud Computing

SBA Communications

A best-in-class tower compounder having its worst year in a decade — 2026 AFFO/share is guided DOWN on DISH+Oi+Sprint churn and refinancing, and the M&A premium has fully bled out of the stock; structurally bullish for 3Y, but no rush at 15.5x AFFO with the churn cliff still in front of it.

AI-Bio

Schrodinger

A genuinely moated physics-based drug-design platform stapled to a cash-burning pipeline it can no longer afford to develop — the software is finally being valued like software (2.5x EV/sales), and the hosted transition is depressing the very revenue line the market punishes hardest. Buy the platform, not the headline P&L; the re-rate needs ACV reacceleration + one partnered pipeline win, not a clinical miracle.

Energy

Shoals Technologies

A re-accelerating solar-EBOS niche-monopolist (FY26 guided +30%, record $758M backlog, IP win pending) trading at ~27x fwd P/E on a near-empty balance sheet ($1.9M cash, revolver 91% drawn) — the growth is real but the equity is priced for it and the funding runway is the actual risk, not the (now-settled) shrinkback overhang.

Semiconductors

Silicon Laboratories

This is no longer a chip stock — it's a near-closed merger-arb. TI buys SLAB for $231 cash; HSR cleared and shareholders approved, only China SAMR left, ~6% gross spread to close in 1H2027. The trade is deal certainty, not IoT growth.

AI-Bio

Simulations Plus

A profitable biosimulation pure-play that the public market broke (Pro-ficiency wrote off ~$72M of a $100M deal, growth fell to single digits) — and is now exiting via a $18.50/sh all-cash Altaris take-private. The fundamental thesis is moot; the only live question is deal-closes-vs-breaks, and this closes (board-unanimous, 16% founder block locked, Q4-2026 close). Merger-arb, not a growth bet.

Semiconductors

SiTime

The MEMS-timing monopolist is being bid as if it has already won the AI clock — at ~35x sales and ~85x forward earnings, a flawless +88% quarter and the transformational Renesas deal are not just priced in, they are required.

Semiconductors

SkyWater Technology

SKYT is no longer a foundry — it is an IonQ deal-stub trading $38.40 vs a $35.00 closed-vote merger value, i.e. a +10% premium that is pure leveraged FTC-cleared bet on IonQ rallying past $60.13; the standalone foundry (43% Infineon, negative op cash flow, $22M cash) is the break-case floor, not the thesis.

Crypto & Digital Assets

SoFi Technologies

A profitable, fast-growing digital bank mispriced as a crypto name and now mispriced again by fear — but the entire bull/bear hinges on one binary question the market cannot yet resolve: are the +$2.0B of fair-value loan marks real, or is Muddy Waters right?

Energy

SolarEdge Technologies

A real turnaround that has already been paid for — six straight quarters of margin repair and the return to positive operating cash flow are genuine, but at ~$60 the stock prices in a clean, AMPTC-independent recovery the filings explicitly say does not yet exist (ex-45X credits, SolarEdge is still gross-loss-making), so the asymmetry from here is poor.

Critical Materials

Southern Copper

The world's lowest-cost, longest-reserve, highest-margin copper pure-play — a generational asset wrapped in a Sell-rated price and 88.9% Grupo Mexico control; you want the orebody, not the multiple, and the market agrees.

Critical Materials

Steel Dynamics

Best-in-class low-cost EAF compounder riding a tariff-fattened spread into a stock that already prices the good news — the edge is the aluminum option and through-cycle discipline, not the current multiple.

Genomics

Stoke Therapeutics

A one-asset, binary bet on a genuinely best-in-class disease-modifying Dravet drug whose pivotal read-out (mid-2027) lands inside a fully-funded runway — own it for the read-out, but size it like the 50/50 single-trial event it is.

Biopharma

Structure Therapeutics

Best-in-class *oral* GLP-1 efficacy in the wrong race — Structure has a genuine #2 asset and a fortress balance sheet, but Lilly's orforglipron is already approved (Foundayo, Apr 2026) and Structure's Phase 3 only *starts* Q3 2026, so the bet is whether a 2.9B-cap, ~2030-launch latecomer can carve share against the most powerful franchise in pharma. WATCHING, not yet a position.

Energy

Sunrun

A consolidating monopolist on a leveraged treadmill — RUN's GAAP "profit" is an HLBV mirage, but the OBBBA's asymmetric kill of 25D (not 48E) hands the TPO leader the residential market it can't yet profitably finance; the bet is whether ~$15B of non-recourse debt rolls before rates or a securitization-market hiccup forces a dilutive reset.

Cloud Computing

Super Micro Computer

A real AI-server demand engine (sold-out Blackwell, $39B order book, best-in-class DLC liquid cooling) wrapped in the worst governance dossier in large-cap tech — a co-founder/director under federal export-control indictment, still-unremediated SOX material weaknesses, ~10% gross margins half of Dell's, and a freshly-printed $7B dilutive raise. The business works; the trust does not. WATCHING, not ownable, until the forensic overhang resolves.

Cloud Computing

Talen Energy

A small-float nuclear-and-gas IPP that turned one AWS contract into a re-rating; the moat is the irreplaceable 2.5 GW Susquehanna campus, the risk is that the price already capitalizes a decade of PJM scarcity and premium PPAs that policy can cap.

AI-Bio

Tempus AI

A real, fast-growing oncology-data + diagnostics franchise wrapped in an "AI" narrative it can't yet monetize — own the genomics flywheel, but the round-trip-flavored deals, 30-vote founder, and a CEO famous for cashing out cap the multiple until cash flow turns.

Critical Materials

Tronox Holdings

The world's #1 vertically-integrated TiO2 producer is a high-quality asset trapped under an 11.1x-levered balance sheet in the worst pigment down-cycle in a decade — the equity is a leveraged call option on a 2027 cyclical recovery (plus a free rare-earth lottery ticket), not an investment, and the 2029 maturity wall is the clock.

Critical Materials

United States Antimony

A ~$1.1B market cap wrapped around a ~$40M-revenue, loss-making smelter — the only US vertically-integrated antimony producer, priced almost entirely on a back-end-loaded $125M federal-ramp promise from a serially-promotional CEO; own the antimony scarcity story, but the equity is a momentum/policy option, not a value asset.

Cloud Computing

Uniti Group

A $2.8B equity wafer balanced on an $11B junk-rated debt tower — the whole thesis is whether Kinetic fiber penetration ramps EBITDA fast enough to delever before the 2028–2031 maturities, and the market has already paid up for that bet.

Critical Materials

Uranium Energy

A leveraged, no-reserves bet on the U.S. uranium-independence trade dressed as an operating miner — production is real but trivial, the share count is the business model, and at ~300x sales you are paying for the spot price and the policy narrative, not the P&L.

AI-Bio

Veeva Systems

A fortress-margin vertical-SaaS monopoly trading at a growth-stock funeral price (~20x forward EPS, near 52-wk lows) because the market is pricing a Salesforce-Agentforce CRM war that threatens the contested ~40% (Commercial) while ignoring the defensible, faster-growing ~60% (R&D/Quality); BULLISH at $153 on a 1–3Y view, but the CRM-migration-to-2030 is a real, watchable execution overhang — not a phantom.

Genomics

Verve Therapeutics

Not a stock anymore — a closed M&A. Lilly bought the whole company for $10.50/share cash (closed Jul 2025); the only live "position" is the $3.00 CVR, which pays only if VERVE-102 reaches a US Phase 3 dosing — market priced ~21% odds, a coin-flip dressed as a lottery ticket.

Biopharma

Viking Therapeutics

The best obesity asset not yet owned by Big Pharma — but the market has already priced in a near-perfect Phase 3, leaving a binary 2027 readout where the upside is a takeout and the downside is a trap-door; SC maintenance data in Q3 2026 is the next real tell.

Cloud Computing

WhiteFiber

A real, cash-generating neocloud retrofitter trading at ~18x trailing sales on a single $865M Nscale contract and a still-71%-Bit-Digital-controlled cap table — the build is genuine, but the multiple already prices the NC-1 inflection that hasn't happened yet.